Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Mechanical Stimulation Triggers Bone Growth

July 21, 2010 7:50 am | News | Comments

A long-standing question in bone biology has been answered: It is the spindly extensions of bone cells that sense mechanical stimulation and signal the release of bone-growth factors.


Antibiotic-Infection Tag Team Promising Against Malaria

July 21, 2010 7:47 am | News | Comments

If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections.


Stem Cells Mitigate Aftermath of Heart Attacks

July 21, 2010 7:31 am | News | Comments

Implanting tiny plastic scaffolds seeded with genetically engineered stem cells reduced organ damage and led to better cardiac function after a heart attack, according to a recent animal study.


Deuterium Swap Results In Better Fluorescent Probes

July 21, 2010 7:17 am | News | Comments

By swapping out one specific hydrogen atom for an isotope twice as heavy, researchers have increased the shelf life and detection ability of fluorescent probes that are essential to studying a variety of inflammatory diseases, including cancer and atherosclerosis.


Important Prostate Cancer Pathway Blocked

July 21, 2010 7:09 am | News | Comments

Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow prostate tumors to produce androgens could be the key in halting the cancer's growth.


Gilead Q2 Revenues Jump 17% From Previous Year

July 21, 2010 6:53 am | News | Comments

Gilead Sciences, Inc. announced that its total revenues for the second quarter of 2010 were $1.93 billion, up 17% compared to total revenues of $1.65 billion for the second quarter of 2009.


Panel Pans Avastin Breast Cancer Approval

July 21, 2010 6:29 am | by Matthew Perrone | News | Comments

A panel of cancer experts said that the government should remove its endorsement of Roche's drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients.


GSK Legal Woes Take Toll on Profits

July 21, 2010 6:22 am | by Robert Barr | News | Comments

GlaxoSmithKline, the world's second-largest pharmaceutical company by revenue, reported a loss of $464 million for the second quarter as the company absorbed a hit of $2.4 billion for settling lawsuits.


Abbott Profits Steady in Second Quarter

July 21, 2010 6:19 am | News | Comments

Abbott Laboratories said its net income was unchanged in the second quarter as greater expenses canceled out higher revenue from Abbott's drugs and medical devices and from companies it recently acquired.


Integrated Raman Imaging System

July 20, 2010 8:36 am | Product Releases | Comments

Veeco Instruments Inc. announces the release of the IRIS models for Innova and BioScope Catalyst atomic force microscopes to provide superior integration and accessibility for combined atomic force microscopy and Raman spectroscopy research.


Magnetic Beads

July 20, 2010 8:29 am | Product Releases | Comments

AMSBIO has announced a new range of MagSi magnetic beads that incorporate a novel ferro fluid to combine the advantages of small beads and large surface with the magnetic performance and strength of larger beads.


Pharsight Names 5 Phoenix Centers of Excellence

July 20, 2010 8:11 am | News | Comments

Pharsight has named five leading universities as Phoenix Centers of Excellence as part of its continuing collaboration with academic departments and research organizations worldwide.


J & J Posts 7.5% Increase in Earnings

July 20, 2010 8:06 am | News | Comments

Healthcare giant Johnson & Johnson posted a 7.5 percent increase in second-quarter income despite ongoing recalls of popular nonprescription medicines keeping sales flat.


ZIOPHARM Begins Phase 3 Sarcoma Trial

July 20, 2010 8:03 am | News | Comments

ZIOPHARM Oncology, Inc. announced the initiation of the pivotal Phase 3 clinical trial for palifosfamide (Zymafos) in patients with front-line metastatic soft tissue sarcoma.


Phase 3 Tapentadol Study Finds Fewer GI Problems

July 20, 2010 7:45 am | News | Comments

A Phase 3 open-label study, recently published online, has compared tapentadol extended release (ER) tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release (CR) tablets.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.